Overview

Comparison of 2 Different Indomethacin Dosing Protocols to Treat Infants Delivered at <28 Weeks Gestation With a Persistent Patent Ductus Arteriosus

Status:
Completed

Trial end date:
2006-07-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to examine if a higher dose of indomethacin will increase the rate of ductus arteriosus closure in extremely premature infants without increasing the side effects. The long term objective is to find the optimal dosing of indomethacin for permanent closure of the Ductus and prevent the morbidity related to PDA and the complications of surgical ligation.

Phase:

Phase 2

Details

Lead Sponsor:

University of California, San Francisco

Treatments:

Indomethacin